Society For Translational Oncology Inc
Society For Translational Oncology Inc maintains strong assets despite fluctuating revenues and recent operating loss.
EIN: 203186261 · Durham, NC · NTEE: H30 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $946K |
| Total Expenses | $723K |
| Program Spending | 85% |
| Net Assets | $1.4M |
| Transparency Score | 88/100 |
Is Society For Translational Oncology Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Society For Translational Oncology Inc directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Society For Translational Oncology Inc
Society For Translational Oncology Inc (EIN: 203186261) is a nonprofit organization based in Durham, NC, classified under NTEE code H30. The organization reported total revenue of $946K and total assets of $1.5M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Society For Translational Oncology Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Society For Translational Oncology Inc is a small nonprofit that has been operating for 17 years, with 14 years of IRS 990 filings on record (2010–2023). Revenue has grown at a compound annual rate of -7.2%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $467K |
| Total Expenses | $723K |
| Surplus / Deficit | $-255,529 |
| Total Assets | $1.5M |
| Total Liabilities | $119K |
| Net Assets | $1.4M |
| Operating Margin | -54.7% |
| Debt-to-Asset Ratio | 7.8% |
| Months of Reserves | 25.3 months |
Financial Health Grade: B
In 2023, Society For Translational Oncology Inc reported a deficit of $256K with expenses exceeding revenue, holds 25.3 months of operating reserves (strong position), has a debt-to-asset ratio of 7.8% (very low leverage).
Financial Trends
Over 14 years of filings (2010–2023), Society For Translational Oncology Inc's revenue has declined at a compound annual growth rate (CAGR) of -7.2%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -66.9% | -18.4% | -16.7% |
| 2022 | +19.9% | +59.7% | +34.0% |
| 2021 | +312.6% | +185.2% | +83.3% |
| 2020 | -26.7% | -44.4% | +26.5% |
| 2019 | -34.6% | -49.4% | +7.2% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2009 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Society For Translational Oncology Inc with a Mission Score of 88 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Society For Translational Oncology Inc allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $256K, with expenses exceeding revenue.
- Debt-to-asset ratio: 7.8%.
Executive Compensation Analysis
Executive compensation is reported as 0% across all available filings, indicating that no officers receive salaries from the organization. This suggests a highly volunteer-driven leadership or that compensation is covered by other means, which is a positive indicator for resource allocation towards the mission.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Society For Translational Oncology Inc's IRS 990 filings:
- Significant year-over-year revenue volatility, with a drop from $1,410,812 in 2022 to $467,002 in 2023.
- Expenses ($722,531) exceeded revenue ($467,002) in the most recent filing (202312), resulting in an operating deficit.
Strengths
The following positive indicators were identified for Society For Translational Oncology Inc:
- Consistent reporting of 0% officer compensation, indicating efficient use of funds for mission-related activities.
- Strong asset base ($1,476,634 current assets) provides financial stability despite revenue fluctuations.
- History of significant surpluses in prior years (e.g., 2021 and 2022) demonstrates capacity for strong financial performance.
- Low liabilities relative to assets, with liabilities at $118,825 in 2023 against assets of $1,525,997.
Frequently Asked Questions about Society For Translational Oncology Inc
Is Society For Translational Oncology Inc a legitimate charity?
Society For Translational Oncology Inc (EIN: 203186261) is a registered tax-exempt nonprofit based in North Carolina. Our AI analysis gives it a Mission Score of 88/100. It has 14 years of IRS 990 filings on record. Total revenue: $946K. 2 red flags identified. 4 strengths noted. Financial health grade: B.
How does Society For Translational Oncology Inc spend its money?
Society For Translational Oncology Inc directs 85% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Society For Translational Oncology Inc tax-deductible?
Society For Translational Oncology Inc is registered as a tax-exempt nonprofit (EIN: 203186261). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What percentage of Society For Translational Oncology Inc's spending goes to programs?
Society For Translational Oncology Inc directs 85% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Society For Translational Oncology Inc compare to similar nonprofits?
With a transparency score of 88/100 (Excellent), Society For Translational Oncology Inc is above average for NTEE category H30 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Society For Translational Oncology Inc located?
Society For Translational Oncology Inc is headquartered in Durham, North Carolina and files with the IRS under EIN 203186261. It is classified under NTEE code H30.
How many years of IRS 990 filings does Society For Translational Oncology Inc have?
Society For Translational Oncology Inc has 14 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $946K in total revenue.
How does the organization sustain itself with 0% officer compensation?
The consistent reporting of 0% officer compensation suggests that leadership may be volunteer-based, compensated through other affiliated entities, or that the organization operates with a very lean administrative structure where key personnel are not directly salaried by the nonprofit itself. Further investigation into their operational model would clarify this.
What caused the significant revenue drop in 2023 ($467,002) compared to 2022 ($1,410,812)?
The substantial decrease in revenue from $1,410,812 in 2022 to $467,002 in 2023 warrants further inquiry. This could be due to the completion of a major grant, a reduction in fundraising activities, or a shift in funding cycles. Understanding the cause is crucial for assessing future financial stability.
Is the recent operating loss in 2023 ($722,531 expenses vs. $467,002 revenue) a concern for long-term viability?
While the 2023 operating loss is notable, the organization has a history of significant surpluses in prior years (e.g., 2022 and 2021) and maintains a healthy asset base of $1,525,997. A single year's loss, especially following strong performance, may not indicate long-term viability issues, but it should be monitored.
Filing History
IRS 990 filing history for Society For Translational Oncology Inc showing financial trends over 14 years of public records:
Over 14 years of IRS 990 filings (2010–2023), Society For Translational Oncology Inc's revenue has declined by 62.3%, moving from $1.2M to $467K. Total assets increased by 121.8% over the same period, from $688K to $1.5M. Total functional expenses fell by 32.8%, from $1.1M to $723K. In its most recent filing year (2023), Society For Translational Oncology Inc reported a deficit of $256K, with expenses exceeding revenue. The organization holds $119K in liabilities against $1.5M in assets (debt-to-asset ratio: 7.8%), resulting in net assets of $1.4M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $467K | $723K | $1.5M | $119K | — | — |
| 2022 | $1.4M | $885K | $1.8M | $135K | — | View 990 |
| 2021 | $1.2M | $554K | $1.4M | $74K | — | View 990 |
| 2020 | $285K | $194K | $746K | $65K | — | View 990 |
| 2019 | $389K | $350K | $590K | $0 | — | View 990 |
| 2018 | $595K | $690K | $550K | $0 | — | View 990 |
| 2017 | $547K | $652K | $646K | $0 | — | View 990 |
| 2016 | $302K | $591K | $778K | $0 | — | View 990 |
| 2015 | $931K | $794K | $1.1M | $0 | — | View 990 |
| 2014 | $1.1M | $873K | $1.0M | $30K | — | View 990 |
| 2013 | $1.4M | $1.0M | $742K | $0 | — | View 990 |
| 2012 | $1.3M | $1.6M | $384K | $0 | — | View 990 |
| 2011 | $945K | $894K | $740K | $0 | — | View 990 |
| 2010 | $1.2M | $1.1M | $688K | $0 | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $467K, expenses of $723K, and assets of $1.5M (revenue -66.9% year-over-year).
- 2022: Revenue of $1.4M, expenses of $885K, and assets of $1.8M (revenue +19.9% year-over-year).
- 2021: Revenue of $1.2M, expenses of $554K, and assets of $1.4M (revenue +312.6% year-over-year).
- 2020: Revenue of $285K, expenses of $194K, and assets of $746K (revenue -26.7% year-over-year).
- 2019: Revenue of $389K, expenses of $350K, and assets of $590K (revenue -34.6% year-over-year).
- 2018: Revenue of $595K, expenses of $690K, and assets of $550K (revenue +8.7% year-over-year).
- 2017: Revenue of $547K, expenses of $652K, and assets of $646K (revenue +81.0% year-over-year).
- 2016: Revenue of $302K, expenses of $591K, and assets of $778K (revenue -67.5% year-over-year).
- 2015: Revenue of $931K, expenses of $794K, and assets of $1.1M (revenue -17.7% year-over-year).
- 2014: Revenue of $1.1M, expenses of $873K, and assets of $1.0M (revenue -19.6% year-over-year).
- 2013: Revenue of $1.4M, expenses of $1.0M, and assets of $742K (revenue +12.2% year-over-year).
- 2012: Revenue of $1.3M, expenses of $1.6M, and assets of $384K (revenue +32.6% year-over-year).
- 2011: Revenue of $945K, expenses of $894K, and assets of $740K (revenue -23.8% year-over-year).
- 2010: Revenue of $1.2M, expenses of $1.1M, and assets of $688K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Society For Translational Oncology Inc:
Data Sources and Methodology
This transparency report for Society For Translational Oncology Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.